> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 2 ANDAs Approved for Generic Sensipar
- URL: https://www.fdaweb.com/2-andas-approved-for-generic-sensipar/
- Published: 2018-03-09T12:00:00.000Z
- Updated: 2026-09-14T23:28:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140948

FDA has approved two ANDAs from Cipla Limited and Aurobindo Pharma for the first generic versions of Amgen’s Sensipar (cinacalcet hydrochloride) tablets for treating a thyroid issue in certain patients on dialysis. The drug is also indicated for treating hypercalcemia in adult patients with parathyroid carcinoma, and severe hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy. Earlier this year, the DC federal court backed FDA’s decision not to grant Amgen’s Sensipar six months pediatric exclusivity ([see story](https://www.fdaweb.com/court-rejects-amgen-sensipar-exclusivity/)).